Peptide education
Vesugen
Vesugen, also spelled Vezugen, is the tripeptide Lys-Glu-Asp, usually abbreviated KED in the literature. It gets discussed as a vascular bioregulator because that is what its small human record actually covers: two older Russian reports, one on penile artery blood flow in vasculogenic erectile dysfunction, one on chronic lower-limb arterial insufficiency. Around that narrow thread the market has wrapped circulation, cholesterol, blood-pressure, longevity, and mitochondrial claims the record does not contain.
Vesugen has a real but tiny human footprint: two older Russian vascular reports with almost no public method detail. The longevity and mitochondrial marketing is not a summary of that record; even the 2024 cell study on this page found no mitochondrial effect for KED.
Overview
Quick answer
The name is used for several different things: literature-defined KED, research-use lyophilized vials, Russian or Eurasian oral capsules, lingual products, and broader peptide-complex supplements. Those products are not identical just because the label says Vesugen or Vezugen.
What is Vesugen?
Vesugen is KED, a three-amino-acid peptide of lysine, glutamic acid, and aspartic acid, from the Khavinson short-peptide bioregulator literature. Russian retail channels may spell it Vezugen.
Why do people talk about it?
Two older Russian human reports gave it a vascular reputation: one in vasculogenic erectile dysfunction reporting improved penile artery flow, one in lower-limb arterial insufficiency reporting clinical and ultrasound improvement. Endothelial-cell and aging-marker studies added mechanism interest, and sellers turned both into a much longer claim list.
What route and exposure patterns are documented?
None that you could repeat. The public human abstracts do not state route, amount, timing, or duration. What is documented is the market split: research-use vials in English-language shops, capsule and lingual Vezugen products in Russian and Eurasian retail.
How strong is the evidence?
Low-certainty, even for the vascular claims it earns honestly. Reversing atherosclerosis, normalizing blood pressure, lowering cholesterol, extending lifespan, or acting as a mitochondrial peptide would each need evidence that is not in this record.
Reported practice
Commonly reported protocol
No established community protocol. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Literature identifies Vesugen as the tripeptide KED, also described as lysyl-glutamyl-aspartic acid.
The clearest human evidence comes from older reports in vasculogenic erectile dysfunction linked with atherosclerosis and chronic arterial insufficiency of the lower limbs.
Cell and review papers discuss endothelial proliferation, Ki-67 promoter interaction, stem-cell aging markers, senescence markers, and neuronal differentiation.
Aging-biology papers make Vesugen biologically relevant, but the 2024 induced-neuron paper did not show a tripeptide effect on mitochondrial activity in that model.
Market material uses the Vesugen/Vezugen name across different formats and sometimes broader peptide-complex language, which creates identity and quality questions.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Vesugen is a vascular bioregulator. | Older human reports in vascular settings explain the vascular label, but they are too narrow and hard to judge from public abstracts to make Vesugen a general vascular treatment. | Endothelial-cell work reported effects on Ki-67 and a promoter-docking hypothesis, and other papers discuss aging-marker or differentiation biology. | Vendor and retail pages often use vascular-health language, sometimes next to circulation, cholesterol, blood-pressure, or anti-aging claims. | Vesugen is vascular-focused, but the available reports are too weak to show that it reliably treats vascular disease. |
| Vesugen improves erectile function or penile blood flow. | One older PubMed-indexed Russian report in men with vasculogenic erectile dysfunction associated with atherosclerosis reported improved main penile artery blood flow after Vezugen treatment. | A vascular peptide rationale fits the topic, but mechanism papers by themselves are not erectile-function outcome evidence. | Seller and explainer pages do not provide the kind of controlled modern ED evidence that would make this a strong use claim. | A low-certainty investigational signal, not a reliable ED therapy claim. |
| Vesugen improves lower-limb circulation. | One older Russian report in chronic arterial insufficiency of the lower limbs described clinical and ultrasound improvement after Vezugen monotherapy. | Endothelial and vasoprotective mechanism papers give the claim a mechanism to discuss. | Retail and vendor material extends the circulation rationale into broader cardiovascular wellness language. | Weak and preliminary. The public details do not provide enough sample-size, comparator, adverse-event, and follow-up information for a confident clinical conclusion. |
| Vesugen reverses atherosclerosis or normalizes cardiovascular markers. | The older vascular reports are not broad atherosclerosis reversal, blood-pressure normalization, cholesterol lowering, or arrhythmia treatment. | Vascular-cell biology can explain why sellers talk this way, but cell markers are not clinical endpoints. | Seller and consumer supplement material carries many of the most sweeping cardiovascular claims. | That goes well beyond the current evidence. Better human outcomes data would be needed before it could be written confidently. |
| Vesugen is a longevity or mitochondrial peptide. | The published human evidence found here does not test Vesugen as a human lifespan, healthy-aging, or mitochondrial-performance intervention. | KED appears in aging-marker and induced-neuron papers, but the induced neuron model reported no tripeptide effect on mitochondrial activity, lysosomal activity, or p16 in that assay. | Online anti-aging language is common because the molecule is often grouped with Khavinson bioregulator products. | The evidence supports aging-biology relevance, but human longevity and direct mitochondrial claims lack human outcome or target-engagement data. |
| Vesugen is safe or side-effect free. | The available human evidence is small, older, and does not provide a modern safety package with comprehensive adverse-event tables, pharmacokinetics, interactions, reproductive toxicology, or long-term follow-up. | A short sequence does not remove safety questions. Route, formulation, exposure, immune response, impurities, and product controls still matter. | Supplement and vendor material may use reassuring language, but clinical safety still depends on actual adverse-event and exposure data. | Too little is known to call it side-effect free, contraindication free, or low-risk across current product forms. |
Bottom line
Main takeaway
Vesugen is a short vascular-research peptide, not an established circulation, heart, longevity, or mitochondrial therapy. Its human record fits in two paragraphs.
Russian capsules, lingual products, research vials, and literature KED are different product situations sharing one name. Identity and form have to be pinned down before any claim can be weighed.
The load-bearing sources are the two older vascular human reports, the endothelial Ki-67 paper, the aging-marker studies, and the 2024 induced-neuron paper, the last of which cuts against the mitochondrial marketing. Product listings show how far the market language has drifted from all of them.
Identity
What it is
Vesugen is KED: lysine, glutamic acid, aspartic acid, in that order. It belongs to the Khavinson bioregulator family, the Russian short-peptide tradition that assigns small peptides to organ systems; KED was assigned to blood vessels.
The assignment is not pure fiction. Older Russian reports describe improved main penile artery blood flow in men with vasculogenic erectile dysfunction, and clinical plus ultrasound improvement in chronic lower-limb arterial insufficiency, after Vezugen. Those reports are the entire human case, and they are old, abstract-level, and missing the methods detail a modern reader needs to judge them.
Everything beyond that is wrapping paper. The circulation, cholesterol, blood-pressure, longevity, and mitochondrial language comes from sellers, and the 2024 induced-neuron study often cited in this context found dendritic effects for KED but no effect on mitochondrial activity. Meanwhile the name floats across vials, capsules, lingual products, and peptide-complex supplements that may not be the same product at all.
How people talk about it online
English-language vendors sell Vesugen as a research-use lyophilized peptide. That framing describes availability; it does not verify that a vial matches the published KED literature on identity, sterility, impurities, or stability.
Russian and Eurasian consumer channels sell Vezugen as capsules and lingual products, sometimes under supplement or peptide-complex language, and a Russian supplement listing is not medicine approval. Same name, different product situation.
The claim lists are the tell: circulation, atherosclerosis, blood pressure, cholesterol, arrhythmia, cerebral blood flow, anti-aging. The human papers on this page cover two narrow vascular settings. The rest of the list has no source behind it here.
Use context
Routes, doses, and cycle patterns
Vesugen has more product-form context than usable clinical regimen detail. The public human abstracts do not provide a reliable route, amount, frequency, or cycle schedule. What the sources do show is the market split: English-language sellers present research-use lyophilized vials, while Russian and Eurasian channels show capsule or lingual Vezugen products. Those forms explain what people encounter online, not a validated regimen.
Human studies and product labels
Vasculogenic erectile dysfunction paper
- Purpose
- Vascular blood-flow signal in men with vasculogenic ED associated with atherosclerosis
- Context
- Older PubMed-indexed Russian human paper
- Route
- Not stated in the public abstract
- Amount
- Not stated in the public abstract
- Frequency
- Not stated in the public abstract
- Duration
- Not stated in the public abstract
The public abstract-level material reports improved penile arterial blood flow, but it does not provide enough protocol and safety detail to describe a usable regimen.
Chronic arterial insufficiency paper
- Purpose
- Lower-limb blood-flow outcomes
- Context
- Older PubMed-indexed Russian human paper
- Route
- Not available in the public abstract
- Amount
- Not available in the public abstract
- Frequency
- Not available in the public abstract
- Duration
- Not available in the public abstract
The summary reports clinical and ultrasound improvement after Vezugen monotherapy. Sample size, comparator, adverse events, and treatment duration were not available from the available material.
Professional truck-driver combined cytogen paper
- Purpose
- Neurotic-disorder and psychoadaptive outcomes
- Context
- Older human paper involving combined cytogens
- Route
- Combination paper does not isolate a Vesugen-only route
- Amount
- Combination paper does not isolate a Vesugen-only amount
- Frequency
- Combination paper does not isolate a Vesugen-only schedule
- Duration
- Combination paper does not isolate a Vesugen-only course length
This paper involved combined cytogens, with Pinealon plus Vezugen described as part of the largest response. It does not isolate Vesugen as a standalone intervention.
Real-world discussion
No established community protocol
- Purpose
- Vascular and longevity discussion
- Context
- Bioregulator vendors, clinics, and forums
- Route
- Research vials, capsules, and lingual products are marketed; no consistent route pattern is documented
- Amount
- No consistent community range is documented
- Frequency
- Not established
- Duration
- Not established
The public human abstracts do not state route, amount, timing, or duration, and the collected material shows no consistent community course pattern. Shared here as context, not instruction.
What varies
- Identity: KED, Vezugen, AC-2 language, peptide complex, capsule, lingual product, and research vial may refer to different product situations.
- Route: human study route details were unavailable; retail oral or lingual products and research-use vials are different product situations.
- Amount and duration: the public human abstracts did not provide enough detail for a reliable study schedule.
- Goal: vascular-aging discussion is more defensible than broad longevity, mitochondrial, cholesterol, blood-pressure, or arrhythmia claims.
- Quality controls: identity testing, impurities, sterility, endotoxin, storage, chain of custody, and formulation matter more than a seller purity claim alone.
Human data
Human evidence
Two narrow, old, abstract-level reports make up nearly the whole human record: improved penile arterial blood flow in vasculogenic erectile dysfunction associated with atherosclerosis, and clinical and ultrasound improvement in lower-limb arterial insufficiency. A third paper involved combined cytogens, Pinealon plus Vezugen, and cannot isolate Vesugen. None of the three reports route, dose, comparator, or adverse-event detail in public form. The record points to a vascular research lead and nothing broader.
Evidence maturity
Vesugen's human evidence is two narrow, abstract-level Russian vascular reports; modern controlled trials do not exist.
Cell papers tie KED to endothelial proliferation, Ki-67, and aging-marker biology.
Older Russian studies report improved penile arterial flow in vasculogenic ED and ultrasound improvement in lower-limb arterial insufficiency, with sparse public methods.
No modern trial with clear comparators, endpoints, and adverse-event reporting has tested Vesugen for any vascular outcome.
Russian supplement-style capsules and lingual products plus research vials share one name while marketing outruns the data.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Vasculogenic erectile dysfunction associated with atherosclerosis | Men with vasculogenic erectile dysfunction in an older Russian report | Older human clinical report | Investigational Vezugen context | The public abstract reports significantly improved blood flow in the main penile artery after Vezugen treatment, with clinical and objective measures mentioned. | The public abstract does not provide enough protocol detail, sample-size context, comparator detail, adverse-event reporting, or modern replication to support a confident ED claim. | Weak human |
| Chronic arterial insufficiency of the lower limbs | People with chronic lower-limb arterial insufficiency in an older Russian report | Older human clinical report | Investigational Vezugen monotherapy context | The public abstract reports clinical and ultrasound improvement in lower-limb blood flow after Vezugen monotherapy. | Sample size, comparator, route, amount, treatment duration, and adverse events were not available from the public summary. | Weak human |
| Neurotic disorders among professional truck drivers | Professional truck drivers in a behavioral and psychoadaptive setting | Older human paper involving combined cytogens | Combined cytogen use, not isolated Vesugen | PubMed indexing and the visible summary indicate the largest effect was seen with combined cytogens, especially Pinealon plus Vezugen. | Because Vesugen was part of a combined cytogen intervention, this row cannot show whether Vesugen alone affects cognition, sleep, stress, or neuroprotection. | Weak human, combination only |
| Vascular endothelial proliferation and MKI67 hypothesis | Tissue-specific and endothelial cell cultures | Mechanism paper | KED / Vesugen mechanism context | The paper reported increased Ki-67 in relevant cultures and a docking hypothesis involving the MKI67 promoter region. | Cell proliferation and promoter-docking hypotheses are not clinical target engagement or vascular outcomes in people. | Preclinical |
| 2024 induced-neuron aging paper | Induced cortical neurons derived from elderly fibroblasts | In vitro induced-neuron model | KED tested with other short peptides | EDR, KED, and AEDG increased dendritic arborization, but the tripeptides did not affect mitochondrial activity, lysosomal activity, or p16 in that model. | The paper supports a narrow neurobiology discussion but weakens direct mitochondrial marketing for Vesugen. | Preclinical |
Cautions
Safety and unknowns
- Public human safety detail is sparse. No modern adverse-event table, drug-interaction review, pharmacokinetic profile, reproductive toxicology, or long-term cardiovascular safety package.
- Route matters. A capsule, lingual product, and research-use vial can create different exposure and quality questions even when the label uses the same name.
- Broad "no side effects" or "contraindication free" claims are not justified by the human reports available here.
- FDA compounding materials say compounded drugs are not FDA-approved and can carry higher risk because they do not undergo premarket review for safety, effectiveness, or quality.
- Russian dietary-supplement listing context is not medicine approval or disease-treatment evidence.
Product quality
A vial label is only a starting point
The largest product issue is identity. Vesugen/Vezugen appears as KED research material, oral capsules, lingual products, and broader supplement-style products.
A seller COA or purity percentage can describe one tested sample. Injectable peptide questions also include sterility, endotoxin, impurities, fill accuracy, storage, degradation, and chain of custody.
Product-form drift makes claim transfer risky. Literature KED, consumer supplements, and research-use vials need separate identity, sterility, and fill-accuracy evidence.
Identity
The same commercial name may refer to KED, AC-2 language, a peptide complex, a capsule, a lingual product, or a research vial.
Sterility and endotoxin
These matter especially for any injectable product claim; the peptide name alone does not answer them.
Assay and impurities
A purity claim can miss wrong sequence, degradation products, related peptide impurities, residual solvents, and batch-to-batch variation.
Route and formulation
Oral, lingual, and vial products create different exposure questions. Each form requires its own identity, route, and handling evidence before outcomes can be compared.
Storage and shipping
Short peptides can still face stability, temperature, reconstitution, and handling issues depending on formulation and supply chain.
Mechanism
How it is proposed to work
Vesugen's proposed biology comes from short-peptide gene-regulation and tissue-signaling ideas, especially around vascular endothelial cells and aging-related cell markers. It is not a well-established receptor drug with modern human target-engagement evidence.
A vascular-cell paper reported Ki-67 changes and a docking hypothesis involving the MKI67 promoter. That supports mechanistic interest, not a clinical vascular outcome by itself.
Stem-cell and aging-marker papers discuss KED in relation to genes such as IGF1, FOXO1, TERT, TNKS2, and NF-kB, plus senescence and differentiation markers in oral and periodontal stem-cell models.
The 2024 induced-neuron paper is important because it separates dendritic-arborization effects from mitochondrial claims. KED was part of the dendritic signal, but not the mitochondrial-activity signal in that model.
Reviews about ultrashort peptide transport through POT and LAT family members provide a general plausibility argument, but they do not replace Vesugen-specific human pharmacokinetic data.
Vesugen (Lys-Glu-Asp) is a Khavinson-lineage tripeptide positioned for vascular aging claims, with proposed effects on endothelial-cell gene expression from the lineage's literature.
FAQ
Common questions
What is vesugen?
Vesugen is a Khavinson-lineage bioregulator peptide positioned for vascular and longevity claims. Its evidence is the Russian bioregulator literature plus animal and cell work.
What do bioregulator courses look like?
None is documented. The public human abstracts do not state route, amount, timing, or duration, and the collected material shows no consistent community course pattern.
Is there human evidence?
Nothing meeting controlled-trial standards. The claims rest on the lineage's own publications.
Details
Technical details
Sources
References
- 1.
Vesugen identity sources. Identity of Vesugen as KED, Lys-Glu-Asp, lysyl-glutamyl-aspartic acid
- 2.
Erectile dysfunction paper. Older human paper in vasculogenic erectile dysfunction
- 3.
Lower-limb arterial insufficiency paper. Older human paper in chronic arterial insufficiency of lower limbs
- 4.
Pinealon plus Vezugen paper. Combined-cytogen neurobehavioral paper involving Pinealon plus Vezugen
- 5.
Endothelial MKI67 study. Endothelial proliferation and MKI67 promoter-interaction hypothesis
- 6.
MSC aging gene-expression study. Human mesenchymal stem-cell aging gene-expression study
- 7.
Oral stem-cell senescence paper. Oral stem-cell senescence paper
- 8.
Oral stem-cell neuron paper. Neuronal differentiation paper in oral stem cells
- 9.
Induced-neuron aging paper. 2024 induced-neuron aging paper with dendritic but not mitochondrial signal
- 10.
FDA compounded-drug risk context. FDA statements that compounded drugs are not FDA-approved and pose higher risk
- 11.
Russian supplement context. Russian supplement context: MedIQ labels Vezugen as БАД; Rospotrebnadzor says БАД are not medicines and cannot treat disease
- 12.
Research-vial market examples. Research-use vendor examples for lyophilized Vesugen vials
- 13.
Consumer supplement examples. Russian and Eurasian consumer supplement listings, product-form heterogeneity, and overclaiming